HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Cystinuria — Clinical Guidelines

Overview

Cystinuria is a genetic disorder characterized by the impaired reabsorption of cystine and other dibasic amino acids, leading to recurrent cystine stone formation and potential nephrolithiasis. It significantly impacts quality of life, particularly in pediatric patients 1 2.

Diagnosis

Key Diagnostic Criteria: Recurrent urinary cystine stones, elevated cystine in urine, and characteristic hexagonal cystine crystals on microscopy 3.

Recommended Tests: Urinalysis for cystine crystals, 24-hour urine collection to measure cystine excretion, and genetic testing for SLC3A1 mutations 1 3.

Management

First-Line Treatments: Increased fluid intake to enhance urine dilution, dietary modifications to reduce cystine intake, and thiazide diuretics to decrease cystine saturation 8.

Adjunctive Therapies:

- Tiopronin: Oral administration to reduce cystine precipitation and excretion; dosing varies but typically around 100 mg/kg/day 1. - Alpha-mercaptopropionylglycine: Alternative to D-penicillamine with fewer side effects; monitor for hyperlipidemia 7. - Captopril: Case reports suggest efficacy in reducing stone formation in pediatric patients 10. - Acetylcysteine: Potential benefit in reducing cystine disulfide formation; requires larger clinical trials 15.

Special Populations

Pediatrics: Cystine stone management often involves shock wave lithotripsy (SWL), ureteroscopy (URS), and percutaneous nephrolithotomy (PCNL) with varying success rates; medical therapy is crucial for long-term prevention 2.

Comorbidities: Patients may develop complications such as hyperlipidemia with certain therapies (e.g., alpha-mercaptopropionylglycine) 7.

Key Recommendations

Implement aggressive hydration and dietary modifications as initial management strategies to reduce cystine saturation in urine (Evidence: Moderate 8).

Consider tiopronin for patients unresponsive to conservative measures, monitoring for adverse events (Evidence: Weak 1).

Evaluate and manage pediatric patients with a multidisciplinary approach, combining surgical and medical therapies to achieve stone-free status (Evidence: Moderate 2).

Monitor for potential side effects, particularly hyperlipidemia with alpha-mercaptopropionylglycine therapy (Evidence: Weak 7).

Consider alternative therapies like captopril in pediatric cases where traditional treatments are ineffective or poorly tolerated (Evidence: Expert opinion 10).

References

1 Ergül RB, Gürlek IT, Özervarlı MF, Özcan ŞG, Pietropaolo A, Tsaturyan A et al.. Tiopronin safety in cystinuria: first real-world pharmacovigilance analysis using the FDA Adverse Event Reporting System (FAERS): an EAU YAU and Endourology sections review. Pediatric nephrology (Berlin, Germany) 2026. link 2 Ripa F, Pietropaolo A, Geraghty R, Griffin S, Cook P, Somani B. Outcomes of Paediatric Cystine Stone Management: Results of a Systematic Review. Current urology reports 2023. link 3 Lee F, Su R, Lendvay T. Cystinuria crystals: an image from a 14-year-old girl with cystinuria. Urology 2013. link 4 Martens K, Heulens I, Meulemans S, Zaffanello M, Tilstra D, Hes FJ et al.. Global distribution of the most prevalent deletions causing hypotonia-cystinuria syndrome. European journal of human genetics : EJHG 2007. link 5 Jaeken J, Martens K, Francois I, Eyskens F, Lecointre C, Derua R et al.. Deletion of PREPL, a gene encoding a putative serine oligopeptidase, in patients with hypotonia-cystinuria syndrome. American journal of human genetics 2006. link 6 Bosio M, Bianchi ML, Lloyd SE, Thakker RV. A familial syndrome due to Arg648Stop mutation in the X-linked renal chloride channel gene. Pediatric nephrology (Berlin, Germany) 1999. link 7 Siskind MS, Popovtzer MM. Hyperlipidemia associated with alpha-mercaptopropionylglycine therapy for cystinuria. American journal of kidney diseases : the official journal of the National Kidney Foundation 1992. link70130-0) 8 Singer A, Das S. Therapeutic dilemmas in management of cystine calculi. Urology 1991. link80257-8) 9 Wikert GA, Kreder KJ, Sheff CD, Dresner ML. New technique for endourologic treatment of cystine nephrolithiasis. Urology 1989. link90375-0) 10 Sandroni S, Stevens P, Barraza M, Tolaymat A. Captopril therapy of recurrent nephrolithiasis in a child with cystinuria. Child nephrology and urology 1988. link 11 Saitoh E, Kim HS, Smithies O, Maeda N. Human cysteine-proteinase inhibitors: nucleotide sequence analysis of three members of the cystatin gene family. Gene 1987. link90196-x) 12 Martini A, Ravelli A, Viola S, Beluffi G, Verga G. Anuria due to bilateral cystine urolithiasis in an infant. Helvetica paediatrica acta 1986. link 13 Blackburn CR, McLeod JG. CNS lesions in cystinuria. Archives of neurology 1977. link 14 Hackett RE. Cystinuria: a surgical challenge. Urology 1975. link90342-8) 15 Mulvaney WP, Quilter T, Mortera A. Experiences with acetylcysteine in cystinuric patients. The Journal of urology 1975. link66955-6)

Cystinuria